STAT+: Top FDA drug regulator tells staff much is still in flux, as she prepares to retire
Jacqueline Corrigan-Curay, the top FDA drug regulator, acknowledged that much is still in flux at the agency and introduced a new deputy.
WASHINGTON — Outgoing Food and Drug Administration regulator Jacqueline Corrigan-Curay acknowledged to staff that much is still in flux at the agency, weeks before she retires.
“We are leaner and therefore we have to find ways to be efficient and do things in new ways,” she told staff, according to a recording of a town hall meeting obtained by STAT.
She did not say who will be the next leader of the Center for Drug Evaluation and Research once she retires next month. Her retirement is the latest in a series of departures of senior officials at the FDA, who have either chosen to take early retirements, left for other jobs, or been forced out by political appointees.
